![Thomas Zindrick](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Zindrick
Directeur Général chez
GENELUX CORPORATION
Fortune : 2 M $ au 31/05/2026
Profil
Thomas D.
Zindrick is Chairman, President & Chief Executive Officer at Genelux Corp.
since 2023 and Executive Vice Chairman at Aeromics, Inc. since 2018.
Former roles include Director at DNX Biopharmaceuticals, Inc. from 2014 to 2020, Director at Amitech Therapeutic Solutions, Inc. from 2014 to 2021, Attorney at The Dow Chemical Co., and Vice President & Associate General Counsel at Amgen, Inc. from 2008 to 2009.
Education includes undergraduate studies at North Central College and graduate studies at the University of Illinois College of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENELUX CORP. 1,19 % | 11/05/2026 | 532 051 ( 1,19 % ) | 2 M $ | 31/05/2026 |
Postes actifs de Thomas Zindrick
| Sociétés | Poste | Début |
|---|---|---|
| GENELUX CORPORATION | Directeur Général | 28/05/2014 |
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Operates preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke | Directeur/Membre du Conseil | 16/08/2018 |
Anciens postes connus de Thomas Zindrick
| Sociétés | Poste | Fin |
|---|---|---|
Amitech Therapeutic Solutions, Inc | Directeur Général | 01/02/2021 |
DNX Biopharmaceuticals, Inc.
 DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic proteins for the treatment of patients with life-long diseases | Directeur/Membre du Conseil | 01/03/2020 |
| AMGEN INC. | Compliance Officer | 01/01/2008 |
| DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | - |
Formation de Thomas Zindrick
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
92
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
The Dow Chemical Co.
 The Dow Chemical Co. Chemicals: Major DiversifiedProcess Industries Manufactures specialty additives, modifiers and plastic polyethylene products | Process Industries |
Genelux Corp.
 Genelux Corp. Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs and virus strains solutions | Health Technology |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Operates preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke | Health Technology |
North Central College
 North Central College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Law
 University of Illinois College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DNX Biopharmaceuticals, Inc.
DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic proteins for the treatment of patients with life-long diseases | Commercial Services |
Amitech Therapeutic Solutions, Inc |
